Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies

AIDS

Volumn 25, Issue 11, 2011, Pages 1365-1369

  Rockstroh, Jürgen K ^a   Teppler, Hedy ^b   Zhao, Jing ^b   Sklar, Peter ^b   Miller, Michael D ^b   Harvey, Charlotte M ^b   Strohmaier, Kim M ^b   Leavitt, Randi Y ^b   Nguyen, Bach Yen T ^b  

^a UNIVERSITY OF BONN   (Germany)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

HIV 1 subtype; integrase inhibitor; raltegravir; resistance mutations

Indexed keywords

EFAVIRENZ; EMTRICITABINE; INTEGRASE; PLACEBO; RALTEGRAVIR; TENOFOVIR; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; B SUBTYPE HUMAN IMMUNODEFICIENCY VIRUS 1; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION; NON B SUBTYPE HUMAN IMMUNODEFICIENCY VIRUS 1; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VIRUS ISOLATION;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 79959956888     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328348065a     Document Type: Article

References (10)

1. Buonaguro L, Tornesello ML, Buonaguro FM. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol 2007; 81:10209-10219. (Pubitemid 47463296)
2. Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. Differences in resistance mutations among HIV-1 nonsubtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc 2009; 12:1-11.
3. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646-650. (Pubitemid 30070911)
4. Miller M, Witmer M, Stillmock K, Felock P, Ecto L, Flynn J, et al. Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor. Presented at: 16th International AIDS Conference; Toronto, Canada, August 2006 [Abstract THAA0302].
5. Danovich R, Ke Y, Wan H, Nguyen B-Y, Teppler H, Schleif W, et al. Raltegravir has similar in vitro antiviral potency, clinical efficacy, and resistance patterns in B subtype and non-B subtype HIV-1. Presented at: 17th International AIDS Conference; Mexico City, August 2008 [Abstract TUAA02].
6. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796-806.
7. Lennox JL, DeJesus E, Berger DS, Lazzarin A, Pollard RB, Madruga JV, et al. Raltegravir-based compared to efavirenzbased regimens in treatment-naive HIV-1 infected patients: efficacy, durability, subgroup, safety, and metabolic analyses through 96 weeks of follow-up. J Acquir Immune Defic Syndr 2010; 55:39-48.
8. Steigbigel RT, Cooper DA, Kumar PN, Eron J, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
9. Steigbigel RT, Cooper DA, Teppler H, Eron J, Gatell JM, Kumar P, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis 2010; 50:605-612.
10. Rhee S-Y, Liu TF, Kiuchi M, Zioni R, Gifford RJ, Holmes SP, Shafer RW. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 2008; 5:74-84.